This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Outpatient Market Gains on Social Awareness: 3 Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.
Why Is DaVita (DVA) Up 5.6% Since Its Last Earnings Report?
by Zacks Equity Research
DaVita (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Health Insurance Industry Outlook - May 2018
by Zacks Equity Research
Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.
DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.
Is DaVita (DVA) a Great Stock for Value Investors Right Now?
by Zacks Equity Research
Let's put DaVita (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.
DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues
by Zacks Equity Research
Impressive results from Kidney Care business drove DaVita (DVA) in Q4.
DaVita (DVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.
DaVita (DVA) Partners with Epic to Launch EHR for Patients
by Zacks Equity Research
DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.
Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS
by Zacks Equity Research
Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.
CVS-Aetna Deal Leading a Wave of Change in Hospital Sector
by Zacks Equity Research
Increased consolidation is being witnessed in the hospital sector as a defense against invasion by new comers.
Company News For Dec 7, 2017
by Zacks Equity Research
Companies In The News are: PLAY,OXM,HRB,DVA,UNH
DaVita (DVA) Surges: Stock Moves 13.6% Higher
by Zacks Equity Research
DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes
UnitedHealth to Buy DaVita Medical, Expands Optum Business
by Zacks Equity Research
UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model
UnitedHealth Continues Healthcare Shakeup With DaVita Deal
by Benjamin Rains
On Wednesday, only a few days after the CVS (CVS) and Aetna (AET) deal helped shine a light on the quickly changing healthcare industry, UnitedHealth Group (UNH) announced that it will buy a unit of DaVita Inc. (DVA) for nearly $5 billion.
New Strong Sell Stocks for November 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
Should Value Investors Consider DaVita Inc. (DVA) Stock?
by Zacks Equity Research
Let's put DaVita Inc. (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.
DaVita HealthCare (DVA) Down 9.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval
by Zacks Equity Research
The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
by Zacks Equity Research
DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
On Jun 23, we issued an updated research report on Denver, CO-based DaVita HealthCare Partners Inc. (DVA).
Is DaVita a Suitable Stock for Value Investors?
by Zacks Equity Research
Let's focus on DaVita Inc. (DVA) stock and find out if it is a good choice for value-oriented investors right now or not.
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial
by Zacks Equity Research
DaVita Inc (DVA), through its subsidiary DaVita Clinical Research (DCR), recently announced the expansion of its research services to include Alliance Site Network.
DaVita (DVA): What's in the Cards this Earnings Season?
by Zacks Equity Research
DaVita HealthCare Partners Inc (DVA), is expected to report first-quarter fiscal 2017 results on May 2, after market close.